Page last updated: 2024-08-16

thalidomide and seratrodast

thalidomide has been researched along with seratrodast in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	1 (50.00)	2.80

Authors

Authors	Studies
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ	1
Chen, H; Hao, Y; Hu, W; Ou, Y; Sun, P; Yang, Z; Yue, H; Zhang, C; Zhong, X	1

Other Studies

2 other study(ies) available for thalidomide and seratrodast

Article	Year
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship	2012
Seratrodast, a thromboxane A2 receptor antagonist, inhibits neuronal ferroptosis by promoting GPX4 expression and suppressing JNK phosphorylation. Brain research, 2022, 11-15, Volume: 1795 Topics: Animals; Benzoquinones; Epilepsy; Ferroptosis; Glutathione; Heptanoic Acids; Mice; Pentylenetetrazole; Phospholipid Hydroperoxide Glutathione Peroxidase; Phosphorylation; Reactive Oxygen Species; Receptors, Thromboxane A2, Prostaglandin H2; Seizures; Thalidomide; Tumor Suppressor Protein p53	2022

Article

Year

Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.

Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12

Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship

2012

Seratrodast, a thromboxane A2 receptor antagonist, inhibits neuronal ferroptosis by promoting GPX4 expression and suppressing JNK phosphorylation.

Brain research, 2022, 11-15, Volume: 1795

Topics: Animals; Benzoquinones; Epilepsy; Ferroptosis; Glutathione; Heptanoic Acids; Mice; Pentylenetetrazole; Phospholipid Hydroperoxide Glutathione Peroxidase; Phosphorylation; Reactive Oxygen Species; Receptors, Thromboxane A2, Prostaglandin H2; Seizures; Thalidomide; Tumor Suppressor Protein p53

2022